ORs (95% CI) for risk factors other than product type for donor toxicities on the day noted to have the highest level of toxicity (within 48 h of BM collection and day +5 from start of G-CSF for PBSCs), at 1 wk, and at 1 mo after donation
| Time point/event . | Female vs male . | Age, y (compared with 18-30) . | MNC at baseline, ≥ 2.7 vs < 2.7 . | ||
|---|---|---|---|---|---|
| 31-40 . | 41-50 . | 51-61 . | |||
| Pericollection | |||||
| Skeletal pain grades 2-4 | 1.65 (1.51%-1.81%) | 1.08 (0.97%-1.20%) | 0.81 (0.72%-0.91%) | 0.65 (0.55%-0.76%) | 1.20 (1.09%-1.32%) |
| Skeletal pain grades 3-4 | 2.68 (2.06%-3.49%) | 1.28 (0.94%-1.74%) | 0.98 (0.70%-1.38%) | 0.58 (0.33%-1.03%) | |
| Other toxicities grades 2-4 | 1.88 (1.67%-2.12%) | 1.18 (1.02%-1.37%) | 1.05 (0.90%-1.23%) | 0.81 (0.65%-1.02%) | |
| Other toxicities grades 3-4 | 3.24 (1.99%-5.30%) | ||||
| Fatigue grades 2-4 | 1.87 (1.62%-2.16%) | 1.31 (1.12%-1.53%) | |||
| 1 wk after donation | |||||
| Skeletal pain grades 2-4 | 1.78 (1.44%-2.20%) | 1.17 (0.89%-1.55%) | 1.50 (1.13%-1.98%) | 1.41 (0.96%-2.07%) | |
| Other toxicities grades 2-4 | 1.89 (1.46%-2.43%) | 1.53 (1.08%-2.16%) | 1.89 (1.34%-2.67%) | 1.98 (1.27%-3.08%) | |
| Fatigue grades 2-4 | 1.85 (1.38%-2.49%) | 1.75 (1.15%-2.65%) | 2.01 (1.32%-3.06%) | 2.54 (1.52%-4.23%) | |
| 1 mo after donation | |||||
| Other toxicities grades 2-4 | 2.05 (1.23%-3.42%) | ||||
| Time point/event . | Female vs male . | Age, y (compared with 18-30) . | MNC at baseline, ≥ 2.7 vs < 2.7 . | ||
|---|---|---|---|---|---|
| 31-40 . | 41-50 . | 51-61 . | |||
| Pericollection | |||||
| Skeletal pain grades 2-4 | 1.65 (1.51%-1.81%) | 1.08 (0.97%-1.20%) | 0.81 (0.72%-0.91%) | 0.65 (0.55%-0.76%) | 1.20 (1.09%-1.32%) |
| Skeletal pain grades 3-4 | 2.68 (2.06%-3.49%) | 1.28 (0.94%-1.74%) | 0.98 (0.70%-1.38%) | 0.58 (0.33%-1.03%) | |
| Other toxicities grades 2-4 | 1.88 (1.67%-2.12%) | 1.18 (1.02%-1.37%) | 1.05 (0.90%-1.23%) | 0.81 (0.65%-1.02%) | |
| Other toxicities grades 3-4 | 3.24 (1.99%-5.30%) | ||||
| Fatigue grades 2-4 | 1.87 (1.62%-2.16%) | 1.31 (1.12%-1.53%) | |||
| 1 wk after donation | |||||
| Skeletal pain grades 2-4 | 1.78 (1.44%-2.20%) | 1.17 (0.89%-1.55%) | 1.50 (1.13%-1.98%) | 1.41 (0.96%-2.07%) | |
| Other toxicities grades 2-4 | 1.89 (1.46%-2.43%) | 1.53 (1.08%-2.16%) | 1.89 (1.34%-2.67%) | 1.98 (1.27%-3.08%) | |
| Fatigue grades 2-4 | 1.85 (1.38%-2.49%) | 1.75 (1.15%-2.65%) | 2.01 (1.32%-3.06%) | 2.54 (1.52%-4.23%) | |
| 1 mo after donation | |||||
| Other toxicities grades 2-4 | 2.05 (1.23%-3.42%) | ||||
Factors are shown with P < .01 in at least 2 multivariate logistic regression models. Skeletal pain represents pain in at least 1 of the following sites: back, bone, headache, hip, limb, joint, and neck. The severity of skeletal pain is defined as the maximum grade among these pain sites. Other toxicity includes fever in the absence of signs of infection, fatigue, skin rash, local reactions, nausea, vomiting, anorexia, insomnia, dizziness, and syncope. The grade of other toxicity is defined as the maximum grade among these symptoms. MNC indicates mononuclear cell count.